Sanofi Celebrates 50th Anniversary of France - China Relations
Confirms commitment to economic development and public health in China
PARIS, Jan. 27, 2014 (GLOBE NEWSWIRE) -- Sanofi (EURONEXT: SAN and NYSE: SNY)
announced today its participation in the commemoration of the 50^th
anniversary of diplomatic relations between France and the People's Republic
of China. In supporting the celebration, Sanofi affirms its commitment to
economic development and public health in China.
"As one of the first multinational pharmaceutical companies to operate in
China, Sanofi has continually provided innovative healthcare solutions for
patients, expanding in pace with the country's development," said Christopher
A. Viehbacher, Chief Executive Officer, Sanofi. "Our expanding portfolio of
medicines and vaccines allows us to contribute to important public health
issues in China, such as chronic disease management, prevention and food
As one of the commemoration's major sponsors, Sanofi will participate in
scientific events throughout the year in France and China, which will include
Chinese students from select academic institutions in France. Sanofi also
plans to participate in the "Better Healthcare" conference in Beijing with
"Club Santé Chine", an initiative by the French government to help small and
medium enterprises export healthcare products.
China is a showcase for Sanofi's collaborative approach, with many research
and development agreements signed in the past six years, including in the
areas of cancer, stem cells, diabetes and aging diseases. Sanofi partners
include Shanghai Institutes for Biological Sciences, the Tianjin Institute of
Hematology and Peking University. In recognition of the richness of China's
research ecosystem, Sanofi settled management of its Asia-Pacific research and
development activities in China in 2011.
About Sanofi in China
Present in China since 1982, Sanofi is committed to the treatment of chronic
diseases, including through programs on diabetes, cardiovascular diseases and
rare diseases. The Group has 11 regional offices and seven factories producing
medicines, vaccines, animal health and consumer health products. As a global
leader in consumer healthcare, Sanofi signed a joint venture with Minsheng in
2010 and acquired BMP Sunstone in 2011. Sanofi generated € 1.2 billion in
revenues in China in 2012, and employs 8,500 people.
Sanofi, an integrated global healthcare leader, discovers, develops and
distributes therapeutic solutions focused on patients' needs. Sanofi has core
strengths in the field of healthcare with seven growth platforms: diabetes
solutions, human vaccines, innovative drugs, consumer healthcare, emerging
markets, animal health and the new Genzyme. Sanofi is listed in Paris
(EURONEXT: SAN) and in New York (NYSE: SNY).
Relations Presse Relations Investisseurs
Laurence Bollack Sébastien Martel
Tel +33 (1) 53 77 46 46 Tel +33 (1) 53 77 45 45
PDF Version http://hugin.info/152918/R/1757142/593602.pdf
Press spacebar to pause and continue. Press esc to stop.